The quality control department did not undertake all of the required activities.
Inspection Record
Rusan Pharma Canada Inc. — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The change control system was inadequate for ensuring changes are properly documented, evaluated, and/or approved.
The controls put in place for electronic signatures were inadequate. The controls were inadequate for creating, modifying, reviewing, storing, and/or retrieving records.
The availability, content and/or maintenance of the quality agreements between the supplier, fabricator, tester, packager, labeller, distributor, importer, and/or wholesaler was inadequate.
The evidence required to demonstrate compliance with finished product specifications was inadequate.
The assessment, documentation, and/or procedures for considering the resale of returned drugs were inadequate.
The handling of standard operating procedures for good manufacturing practices was inadequate.
About this record
Extracted automatically from the document of the Health Canada inspection on 2026-06-18. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
